Open Access

Table III

Critical analysis of the literature on the efficacy of botulinum toxin in the management of overdrooling in children with cerebral motor problems.

Reference Objective Type of study No. BT dose Duration Judgment criteria Muscle site salivary gland Validity
Reid, 2008 [21] Efficiency: Injection versus no injection Rand, CT, multicenter 48 100 U 12 months Subjective: Q ° parents P + Sb S
6–18 years Botox**
Alrefai, 2008 [22] Efficacy: Injection versus placebo Rand, DB, CT 24 240 U 4 months Subjective: Q ° nurse P + Sb S
21 months to 7 years Dysport**
Jongerius, 2004 [23] Efficiency: injection versus Scopolamine Rand, CT 45 50 U 24 months Subjective: Q ° parents Sb S
3–17 years Botox* Objective: DQ Injection>scopolamine
Suskind, 2002 [24] Efficacy: injection in different glands CT, prospective 22 30 U 1 month Objective: DQ P + Sb S
8–21 years Botox* Cotton salivary test NS difference
Basciani, 2011 [25] Efficiency: 3 different doses versus placebo Rand, CT, prospective 27 1500 U, 3000 U, 5000 U, Neuroblo** 3 months Subjective: Q ° parents P + Sb S
6 months to 7 years   Objective: number of bottles

Rand: randomized; DB: double-blind; CT: clinical trial; U: unit; No.: number; BT: Botulinum toxin; Q: questionnaire; DQ: drooling quotient; P: parotid; Sb: submandibular; NS: not significant; S: significant.

*

By injection.

**

In total.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.